• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Driving Performance and Cannabis Users’ Perception of Safety: A Randomized Trial
RESEARCH UPDATE

Driving Performance and Cannabis Users’ Perception of Safety: A Randomized Trial

January 30, 2023
Olaniyi Olayinka, MD.
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Olaniyi Olayinka, MD. Dr. Olayinka has no financial relationships with companies related to this material.

REVIEW OF: Marcotte TD et al, JAMA Psychiatry 2022;79(3):201–209

STUDY TYPE: Double-blind, placebo-controlled parallel randomized clinical trial

Everyone knows that driving while under the influence of alcohol is dangerous. But what about cannabis? The effect of cannabis on driving ability is not well understood but is becoming increasingly relevant as cannabis laws are liberalized around the nation. Researchers designed a double-blind placebo-controlled trial to determine how THC affects driving ability and how long its effects last.

The study recruited 191 participants who had used cannabis ≥4 times in the past month. Sixty-two percent were male, 43% were non-Hispanic White, and ages ranged from 21 to 55. Participants abstained from cannabis for at least 48 hours and then were randomly assigned to one of three groups: low THC, high THC, or placebo.

On testing day, participants were given cannabis cigarettes and instructed to smoke “as you would at home.” The THC content of the cannabis was 13.4% in the high THC group (comparable to typical whole-plant cannabis purchased at dispensaries today), 5.9% in the low THC group, and 0.02% in the placebo group. Participants completed a driving simulation 30 minutes, 90 minutes, 3.5 hours, and 4.5 hours after smoking. The simulation lasted 25 minutes, emulated urban and city driving, and had challenges such as highway merging, driving while attending to an iPad mounted on the dashboard, and maintaining constant distance from a car being driven at varying speed. Performance was quantified by a Composite Drive Score (CDS), which takes variables like proper speed, time out of lane, and lateral position into account. Serum levels of THC were measured at the time of each driving simulation.

Not surprisingly, drivers in the placebo group had significantly better CDS scores than those in the THC groups. THC had a medium effect size on driving performance at 30 and 90 minutes, but performance was equivalent between groups at the 3.5- and 4.5-hour marks. The low THC and high THC groups had similar impairments in driving performance. Importantly, participants were asked about their subjective perception of their readiness to drive. At 30 minutes, 47.5% in the THC groups said they would drive at their current level of intoxication, and this increased to 68.6% at 1.5 hours.

There were a few limitations to this study. Most notably, 92% of participants correctly guessed whether they received THC. The study recruited healthy participants who regularly used cannabis, so the results may not be generalizable to inexperienced THC users or vulnerable populations (eg, the elderly or those with traumatic brain injury). THC effects could very well be more pronounced or longer lived in these individuals. Authors noted that CDS scores in this study are not directly comparable to impairments in driving for those under the influence of alcohol. For a rough point of comparison, the overall effect size is similar to what would be expected for a blood alcohol level between 0.05% and 0.08%.

Carlat Take

Cannabis consumption impairs driving, even if the THC content is on the low side, and subjective perception is not a good predictor of actual driving ability. Tell your patients who use cannabis to abstain from driving for at least three and a half hours after using, even if they feel safe to drive.

KEYWORDS addiction cannabis marijuana THC
Olaniyi Olayinka, MD.

More from this author
www.thecarlatreport.com
Issue Date: January 31, 2023
SUBSCRIBE NOW
Table Of Contents
Learning Objectives, Addiction Treatment in the ED, CATR, Jan/Feb/Mar 2023
What to Know About Injectable Buprenorphine (Sublocade)
Managing Alcohol Withdrawal in the Emergency Department
Buprenorphine and Dental Issues
Alcohol Use Disorder and Thiamine Supplementation
Thiamine Supplementation in Patients With Alcohol Use Disorder
Driving Performance and Cannabis Users’ Perception of Safety: A Randomized Trial
Is Ibogaine Safe for Opioid Detox?
CME Post-Test, Addiction Treatment in the ED, CATR, Jan/Feb/Mar 2023
DOWNLOAD NOW
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.